Checkpoint Inhibition

Slides:



Advertisements
Similar presentations
Upfront Combination Therapy vs Step-Up Approach for PAH:
Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
Diabetic Dyslipidemia in Practice
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Case Studies.
New Therapies for Hyperkalemia Across the Continuum of Care
New Patient Journeys in Non-small cell lung cancer
Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Endocrine System.
Introduction to Checkpoint Inhibitors
The Tumor Microenvironment
The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.
Activity Goals. Activity Goals Discussion Topics.
Clinical Considerations in Evidence-based Management of GIST
Follow-Up of the Patient After PE
Locally Advanced NSCLC Implementing Innovation
Precision Management of RA and Comorbidities
Optimizing Management of Advanced Bladder Cancer
Improving Management of Type 2 Diabetes in Hispanic/Latino Patients
The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.
Checkpoint Inhibition
Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.
The Emerging Role of Immunotherapy in Hodgkin Lymphoma
Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Gene Therapy: Past, Present, and Future
Introduction. Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Skin.
Managing Adverse Events With New Oral Therapies in CLL
Optimizing Outcomes and Managing Adverse Events in CLL
Immunotherapy for cSCC
Personalized Therapy in Relapsed or Refractory CLL
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Managing Polycythemia Vera in the Community Setting
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Best Clinical Pearls in Hidradenitis Suppurativa:
Locally Advanced Lung Cancer
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Patient Questions and Expert Answers in Psoriasis:
A Guideline-Based Approach to HCV Care
Severe Asthma and Comorbidities
Management of Advanced Pancreatic Adenocarcinoma
Insulin in Diabetes Management: Effective Patient Selection Is Key
Possible Causes of imAEs
Communicating With Your Patients About Major Depressive Disorder
Novel Concepts in the Management of RCC
Debates and Dilemmas, Part 1
Improving Adherence to Antiplatelet Therapy After an ACS Event
The Patient With Early Stage MF-CTCL
From Adjuvant to Metastatic in Melanoma
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
AMD Therapy: Where Are We Now and Where Are We Going?
Checkpoint Inhibitors in First-Line Advanced NSCLC
Clinical Considerations in Evidence-based Management of GIST
The Nurse View: Spotlight on EGFR-Mutated NSCLC
A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors
MS, Age, and Immune Function
Tardive Dyskinesia 101.
Merging the Art and Science of Managing nOH in Clinical Practice
Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.
What's New in PAH?.
Immune Checkpoint Inhibitors in Lung Cancer
The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.
Recent Developments in the Treatment of Advanced and Metastatic RCC
Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.
Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.
Management of NTM Lung Disease
Presentation transcript:

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Lung

Checkpoint Inhibition

Incidence of imAEs

Risk for Pneumonitis

Pneumonitis

Case

Case (cont)

Staging CT/PET Scan

Case (cont)

Repeat Chest CT/PET Scan

Notes on the Case

Diagnostic Workup

Grading Pneumonitis

Management of Grade 1 Pneumonitis

Management of Grade 2 Pneumonitis

Management of Grade 3/4 Pneumonitis

Case (cont)

Restarting Therapy

Treating Patients Who Do Not Respond to Steroids

Concluding Remarks

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.